Ashish C. Bhatia MD, FAAD
Associate Professor of Clinical Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois; Co-Founder, Director of Clinical Research, and Co-Director, Dermatologic, Laser and Cosmetic Surgery, Oak Dermatology, Itasca, Joliet, and Naperville, IllinoisDr. Ashish Bhatia is a board-certified and fellowship-trained dermatologist and dermatologic surgeon. He is an Associate Professor of Clinical Dermatology at Northwestern University Feinberg School of Medicine in Chicago and the Director of Dermatologic, Laser, and Cosmetic Surgery at Oak Dermatology (locations in Itasca, Joliet, and Naperville, Illinois).
Dr. Bhatia is a recognized expert in dermatologic surgery and cosmetic surgery. His clinical expertise includes Mohs and reconstructive surgery, skin cancer therapy and prevention, laser surgery, skin resurfacing procedures, and cosmetic procedures including lasers, fillers, and neuromodulators. He also has a special interest in restorative procedures for adults and children with burns, surgical scars, and traumatic scars.
After receiving his medical degree from Northeastern Ohio University College of Medicine, Dr. Bhatia completed his residency in dermatology at the Medical College of Virginia Hospitals, where he served as Chief Resident. Subsequently, he completed an intensive fellowship in Mohs surgery, cutaneous oncology, and reconstruction, cosmetic, and laser surgery at SkinCare Physicians in Boston, Massachusetts.
Disclosures
- Grants/research: AbbVie; Alastin Skincare; Avita Medical; Cutera; Medline; NovaScan; Pulse Biosciences; R2 Technologies; Revance
- Consulting/advisory boards: Alastin Skincare; Allergan/AbbVie; Arcutis; Avita Medical; Bausch Health; Carpe; Cutera; Cytrellis; Emblation Ltd; Endo Aesthetics; Entrepix Medical; Evolus; Medline; MiMEDx; Obagi; Ortho Dermatologics; RBC Consultants; Revance; Solta; Sofwave; Strata Skin Sciences; Theravant Corp
- Speaker bureau: Allergan; Cutera; DermEd Foundation; Evolus; Medline; MiMEDx; Ortho Dermatologics; Paradigm Medical; Revance; Theravant Corp
- Ownership interest/shareholder: Biomarck; Carpe; Cutera; Derma MD; Genzum; SimSkin; Sonoma; Theravant Corp; Zalea
- Stock/options: AbbVie; Bausch Health; Biomarck; Carpe; Cutera; Cytrellis; Strata Skin Health
- Executive role/board member: Theravant Corp; DermEd Foundation
Recent Contributions to PracticeUpdate:
- Efficacy of Autologous Injectable Platelet-Rich Fibrin With Microneedling vs Microneedling Alone in Patients With Atrophic Acne Scars
- Therapeutic Effectiveness of Needle Injection vs Needle-Free Jet Injector System for Administering Botulinum Toxin Type A in Patients With Palmar Hyperhidrosis
- Association Between Different Oral Corticosteroid Prescribing Patterns and Fracture Preventive Care Among Older Adults in the UK and Ontario
- Neighborhood-Level Socioeconomic Predictors of Melanoma Thickness, Ulceration, and Metastasis
- Efficacy of OnabotulinumtoxinA in Improving Oral Aperture in Patients With Scleroderma
- Long-Term Resolution of Gummy Smile With Repeated Injections of Botulinum Toxins
- Gaps in Access to Biologics for Psoriasis Among the Working Poor
- Comparison of the Efficacy of Combined Silver Nitrate Coagulation and Shave Excision With Surgical Excision and Linear Closure in the Treatment of Pyogenic Granuloma
- Fractional CO2 Laser vs Microneedle Radiofrequency for Acne Scars
- 2022 Top Story in Dermatology: An Ounce of Prevention... With Lasers!